ITCI
Intra-Cellular Therapies Inc
Price:  
67.23 
USD
Volume:  
853,076.00
United States | Pharmaceuticals
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

ITCI EV/EBITDA

-139.7%
Upside

As of 2024-03-05, the EV/EBITDA ratio of Intra-Cellular Therapies Inc (ITCI) is -40.04. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ITCI's latest enterprise value is 6,360.77 mil USD. ITCI's TTM EBITDA according to its financial statements is -158.87 mil USD. Dividing these 2 quantities gives us the above ITCI EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 11.3x - 18.1x 14.0x
Forward P/E multiples 17.6x - 21.6x 20.3x
Fair Price (27.29) - (28.14) (26.66)
Upside -140.6% - -141.9% -139.7%
67.23 USD
Stock Price
(26.66) USD
Fair Price

ITCI EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-03-04 -40.04
2024-03-01 -42.63
2024-02-29 -41.43
2024-02-28 -42.41
2024-02-27 -43.49
2024-02-26 -42.68
2024-02-23 -41.82
2024-02-22 -42.90
2024-02-21 -43.72
2024-02-20 -43.98
2024-02-16 -45.17
2024-02-15 -44.71
2024-02-14 -42.94
2024-02-13 -41.97
2024-02-12 -43.39
2024-02-09 -43.41
2024-02-08 -42.70
2024-02-07 -40.85
2024-02-06 -41.78
2024-02-05 -41.12
2024-02-02 -40.05
2024-02-01 -40.62
2024-01-31 -40.10
2024-01-30 -40.74
2024-01-29 -41.64
2024-01-26 -40.12
2024-01-25 -39.89
2024-01-24 -39.34
2024-01-23 -39.57
2024-01-22 -40.09
2024-01-19 -38.95
2024-01-18 -38.76
2024-01-17 -39.26
2024-01-16 -40.18
2024-01-12 -39.51
2024-01-11 -40.51
2024-01-10 -40.25
2024-01-09 -42.18
2024-01-08 -42.74
2024-01-05 -40.81
2024-01-04 -41.14
2024-01-03 -41.39
2024-01-02 -42.02
2023-12-29 -42.71
2023-12-28 -42.94
2023-12-27 -43.95
2023-12-26 -42.51
2023-12-22 -41.94
2023-12-21 -39.71
2023-12-20 -38.85